The BioPharm Brief: Gene Therapy Reform, Cancer Trial Endpoints, and a $1.2B Rare Disease Deal

Today’s BioPharm Brief covers FDA draft guidance aimed at streamlining rare disease gene therapy development, Phase 3 trial updates involving dual survival endpoints in oncology programs, and Eli Lilly’s $1.2 billion licensing deal for a GLP-2 therapy in short bowel syndrome.